Biotechnology

Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA

* Sales double in the USA, order intake increases by over 150 percent * More than 50 percent increase in order intake in EMEA * Business Area Technology & Services' sales grow by almost 25 percent  * Further improvement in profitability * Exyte CEO Büchele: "Our follow-the-client strategy ...

2024-04-09 17:52 1417

Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

News Summary: * New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsi. * Featuring MaxPeak™ High Performance Surface (HPS) Technology, the new system minimizes unwanted anal...

2024-04-09 14:00 1296

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

PRINCETON, N.J. and SUZHOU, China, April 9, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilen...

2024-04-09 09:18 1319

Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib

SHANGHAI, April 8, 2024 /PRNewswire/ -- 9 April 2024 (Beijing Time), Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment for its pivotal Phase III trial, MANEUVER (ABSK021-301) STUDY, for evaluating the efficacy and safety of pimicotinib in patient...

2024-04-09 08:30 1086

MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China

SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the market...

2024-04-08 22:00 1000

Seegene and UK Health Security Agency convene a summit to collectively realize "a World Free from All Diseases"

* Two CEOs met at Seegene headquarters to discuss and concurred with Seegene's vision * Seegene's swift responses to the COVID-19 pandemic and digital solutions through AI implementation were presented SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Seegene Inc., a leading South Korean comp...

2024-04-08 20:00 1549

SeekIn Presents New OncoSeek® Data at the AACR Annual Meeting in San Diego

Two Sample Types, Three Different Platforms, Six Independent Cohorts of ~12,000 Cancer Patients and Non-cancer Individuals with Diverse Ethnic Backgrounds in Retrospective and Prospective Settings Validate OncoSeek's Ability to Detect Multiple Cancer Types and Predict the Tissue of Origin of Ca...

2024-04-08 20:00 952

Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort

-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralization titers to approximately 6,600 IU/mL (6.4-fold increase) and approximately 46,000 IU/mL (12-fold increase), respectively -- -- Preliminary Phase I data in target older adult population is on track for H2-2024 -- SHANGHAI, ...

2024-04-08 17:19 1284

D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline

SHANGHAI, April 8, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, a leading European life sciences investment firm. D3 Bio'...

2024-04-08 15:00 1050

Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial

MELBOURNE, Australia, April 8, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK...

2024-04-08 08:47 1300

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...

2024-04-08 08:00 1667

AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, April 7, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that it releases the latest results from three pre...

2024-04-08 07:58 990

Antengene Presents Four Preclinical Posters at AACR 2024

SHANGHAI and HONG KONG, April 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for canc...

2024-04-06 08:30 3028

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at th...

2024-04-05 19:00 1446

IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis

SHANGHAI and NANJING, CHINA, and SAN JOSE, Calif., April 4, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, is pleased to announce that the Inve...

2024-04-05 08:00 1429

Huahui Health to Present Preclinical Data of HH018-sesutecan at the 2024 AACR Annual Meeting

BEIJING, April 4, 2024 /PRNewswire/ -- Huahui Health Ltd.("Huahui Health"), a clinical stage biotechnology company focused on discovering and developing virology, hepatology, and oncology therapies, announced that it will present the results of preclinical data of HH018-sesutecan, a tumor microen...

2024-04-04 22:00 1377

IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against Aggressive Brain Tumors and Acute Lymphoblastic Leukemia at AACR

ROME, April 4, 2024 /PRNewswire/ -- IRBM, a leader in the field of drug discovery, announced today that it will be disclosing new data on two of its most promising internal assets at the upcoming American Association for Cancer Research (AACR) Annual Meeting occurring inSan Diego, April 5-10. The...

2024-04-04 21:00 2559

Human Frontier Science Program: Fellowships Awarded to 59 of the Most Pioneering Postdoctoral Scientists from 28 Nations

STRASBOURG, France, April 4, 2024 /PRNewswire/ -- To foster the next generation of life science research, 59 of the world's top emerging scientists from 28 nations have won 2024 Human Frontier Science Program (HFSP) Fellowships. "Brilliance is not born, it has to be cultivated," said HFSP Chief S...

2024-04-04 17:00 2380

SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership

The companies will join forces to advance the use of precision medicine on a global scale BOSTON and ROLLE, Switzerland, April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a s...

2024-04-04 13:00 1870

SYNPET to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024

TAIPEI, April 3, 2024 /PRNewswire/ -- SYNPET, a subsidiary brand of SYNBIO TECH, a leading lactobacillus manufacturer based inTaiwan, is proud to announce its participation at the upcoming Petfood Forum 2024. This premier event for pet food and pet treat manufacturers and industry suppliers will ...

2024-04-04 01:00 1172
123456 ... 278